{
  "docId": "019de074-ddab-749d-b286-5e01e8bcb935",
  "docSlug": "f43e68719e672319f390e5844d5bc5fe",
  "documentTitle": "Chimerix | Investor Presentation Deck | 41 slides",
  "authorId": "chimerix",
  "authorName": "Chimerix",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 13,
  "pageCount": 41,
  "prevPage": 12,
  "nextPage": 14,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 48,
  "notes": "Presents safety data tables for two distinct patient populations.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-ddab-749d-b286-5e01e8bcb935/13",
  "deckHref": "/decks/019de074-ddab-749d-b286-5e01e8bcb935",
  "deckJsonHref": "/decks/019de074-ddab-749d-b286-5e01e8bcb935.json",
  "deckAnchorHref": "/decks/019de074-ddab-749d-b286-5e01e8bcb935#slide-13",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.453,
        "x": 0.024,
        "y": 0.518
      },
      "kind": "list",
      "text": "In addition to healthy adult dose escalation study above, clinical pharmacology studies included: food-effect, safety pharmacology, special populations, and drug-drug interaction studies. Treatment-related AEs were generally Grade 1 and transient across the clinical pharmacology program. The most commonly reported treatment-related events were mild dizziness, headache and nausea.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "597e2031-769b-470d-a2d9-e36b541ed8c6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.26,
        "x": 0.104,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "1. Based on available data as 25Apr2023 for ONC201-101 2. Reported in ONC201 Investigator Brochure",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b58c3048-fca4-4bf2-8a55-434745a67620",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.475,
        "w": 0.408,
        "x": 0.557,
        "y": 0.178
      },
      "kind": "table",
      "text": "Treatment-related Adverse Events in >= 3% Glioma Patients",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "370133cd-d052-4972-b5b7-836e4a532523",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.188,
        "w": 0.447,
        "x": 0.054,
        "y": 0.178
      },
      "kind": "table",
      "text": "Healthy Adult Dose Escalation Study Incidence of ONC201-Related Adverse Events (AE)",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5fa4fe42-2d98-42b3-a765-bf00559e9968",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.035,
        "w": 0.204,
        "x": 0.398,
        "y": 0.06
      },
      "kind": "title",
      "text": "ONC201 safety",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b2e8c6df-39c7-49ff-ab06-55076849bd3b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "52809b69-67e5-499c-b645-b16809115c14",
      "evidence": "Healthy Adult Dose Escalation Study Incidence of ONC201-Related Adverse Events (AE)",
      "confidence": 0.9
    },
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "c1e63378-bead-47a8-abbd-61f1498966d4",
      "evidence": "Treatment-related Adverse Events in >= 3% Glioma Patients",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 14,
      "from": 7,
      "beatId": "7df034ba-8b82-48a9-931a-54c9c4d04f47",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "The deck presents efficacy data for ONC201 in recurrent H3 K27M DMG",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 14,
      "from": 6,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "77a4ca89-6944-4b59-9557-b7e1ac4d70e5",
      "evidence": "The deck presents data on the unmet need and potential benefits of ONC201",
      "position": 0,
      "objective": "Highlight the cost of inaction in treating H3 K27M-mutant diffuse glioma",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}